Mclazide-M 60 XR Tablet is a combination oral hypoglycemic agent containing Gliclazide 60 mg and Metformin 500 mg, formulated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The extended-release (XR) formulation ensures a gradual and sustained release of active ingredients, promoting steady plasma concentrations and reducing the frequency of dosing, which may improve patient compliance. Mclazide-M 60 XR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve target blood glucose levels. It is essential to monitor blood glucose levels regularly and adjust the dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances and hypoglycemia. This combination therapy should be used under medical supervision, with lifestyle modifications, to optimize glycemic control and reduce the risk of diabetes-related complications.